Pacific Edge says it has gained patent protection for its technology being used to develop a melanoma test from the United States Patent Office.
The test will help clinicians distinguish between life-threatening melanomas and those which are not as aggressive.
Chief executive David Darling said while the company's focus is on commercialising its bladder cancer tests, the melanoma test could reach the market relatively soon.
"If they can use this test to segregate those that have aggressive tumours and then put them into their clinical study, they can determine effectively how their new therapeutic will work."
Pacific Edge already has patent protection for the test in New Zealand and China.